Stryker Corp. Hits New 52-Week Low at USD 289.96

Stryker Corp., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 289.96 on May 6, 2026. This significant decline highlights the stock's challenging performance, with a one-year return of -16.04%, contrasting sharply with the S&P 500's impressive gain of 31.36% during the same period. The company's market capitalization stands at USD 133,773 million, categorizing it as a large-cap entity. Stryker's price-to-earnings (P/E) ratio is currently at 33.00, indicating a relatively high valuation compared to its earnings. The stock also offers a dividend yield of 0.97%, reflecting its commitment to returning value to shareholders. Despite its low debt-to-equity ratio of 0.53, Stryker has faced challenges in maintaining robust performance metrics. The return on equity is reported at 17.83%, while the price-to-book ratio is 5.97. The stock's performance has been below par in both the long and near term, as evidenced by its negative returns over the past year and its underperformance relative to the broader market indices.